HKSE - Delayed Quote HKD

Ascentage Pharma Group International (6855.HK)

27.200 -1.020 (-3.61%)

At close: October 30 at 4:08:06 PM GMT+8

How Much Upside is Left in Ascentage Pharma Group International - Unsponsored ADR (AAPG)? Wall Street Analysts Think 152.23%

Zacks 3mo ago

6855.HK
-3.61%
AAPG
Why Ascentage Pharma Group Internat (AAPG) Is Gaining Attention in Cancer Drug Development

Insider Monkey 3mo ago

6855.HK
-3.61%
OPY

AAPG
Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress

GlobeNewswire 4mo ago

6855.HK
-3.61%
6855

AAPG
A Look At Ascentage Pharma Group International’s Valuation After Recent Share Price Weakness

Simply Wall St. 4mo ago

6855.HK
-3.61%
AAPG
Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026

GlobeNewswire 4mo ago

6855.HK
-3.61%
AAPG
Ascentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in CML-CP at ASCO 2026

GlobeNewswire 4mo ago

6855.HK
-3.61%
AAPG
Ascentage Pharma Presents Its First Dataset on MDM2-p53 Inhibitor Alrizomadlin (APG-115) in Pediatric Solid Tumors at ASCO 2026

GlobeNewswire 4mo ago

6855.HK
-3.61%
AAPG
Ascentage Pharma Releases Latest Clinical Data from Multiple Trials at ASCO 2026

GlobeNewswire 5mo ago

6855.HK
-3.61%
AAPG
Ascentage Pharma to Present 17 Clinical Advances at 2026 European Hematology Association Congress

GlobeNewswire 5mo ago

6855.HK
-3.61%
AAPG
Ascentage Pharma to Participate in Three Upcoming Investor Conferences

GlobeNewswire 5mo ago

6855.HK
-3.61%
AAPG
Ascentage Pharma to Present Data from Multiple Trials, Including Three Rapid Oral Presentations, at ASCO 2026

GlobeNewswire 6mo ago

6855.HK
-3.61%
AAPG
Ascentage Pharma to Present Four Promising Preclinical Studies Demonstrating the Potential of Combination Therapies at American Association for Cancer Research (AACR) 2026 Annual Meeting

GlobeNewswire 6mo ago

6855.HK
-3.61%

U.S. markets closed

Ascentage Pharma Group International (6855.HK)

How Much Upside is Left in Ascentage Pharma Group International - Unsponsored ADR (AAPG)? Wall Street Analysts Think 152.23%

Why Ascentage Pharma Group Internat (AAPG) Is Gaining Attention in Cancer Drug Development

Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress

A Look At Ascentage Pharma Group International’s Valuation After Recent Share Price Weakness

Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026

Ascentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in CML-CP at ASCO 2026

Ascentage Pharma Presents Its First Dataset on MDM2-p53 Inhibitor Alrizomadlin (APG-115) in Pediatric Solid Tumors at ASCO 2026

Ascentage Pharma Releases Latest Clinical Data from Multiple Trials at ASCO 2026

Ascentage Pharma to Present 17 Clinical Advances at 2026 European Hematology Association Congress

Ascentage Pharma to Participate in Three Upcoming Investor Conferences

Ascentage Pharma to Present Data from Multiple Trials, Including Three Rapid Oral Presentations, at ASCO 2026

Ascentage Pharma to Present Four Promising Preclinical Studies Demonstrating the Potential of Combination Therapies at American Association for Cancer Research (AACR) 2026 Annual Meeting